Urinary Tract Infections Clinical Trial
— AIDA-WP2Official title:
Randomised Clinical Trial Comparing Fosfomycin vs. Nitrofurantoin for Treatment of Uncomplicated Lower Urinary Tract Infection in Female Adults at Increased Risk of Antibiotic-resistant Bacterial Infection
Verified date | May 2017 |
Source | University Hospital, Geneva |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Developed before the establishment of a structured process for drug assessment, nitrofurantoin is now being prescribed frequently given the rise in multi-resistant gram-negative pathogens. Doubts remain regarding fosfomycin's long-term clinical effectiveness. A randomized, controlled trial is needed to explore the clinical effectiveness and better define the side effect profiles of both nitrofurantoin and fosfomycin. This multi-center open trial will randomize 600 non-pregnant women at three international sites (200 each in Poland, Switzerland, and Israel) at increased risk for carriage of resistant uropathogens and with suspicion of uncomplicated lower urinary tract infection to receive either oral nitrofurantoin 100 mg three times daily for 5 days or a single 3g dose of oral fosfomycin. Patients will be followed for clinical and bacteriologic response at days 14 and 28 post therapy completion. The study hypothesis holds that nitrofurantoin will be superior to fosfomycin in clinical efficacy at final follow-up.
Status | Active, not recruiting |
Enrollment | 600 |
Est. completion date | August 2017 |
Est. primary completion date | May 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Female gender - Age = 18 years - Written informed consent - At least one of four key UTI symptoms that could be attributed to an uncomplicated UTI, and no alternative explanation (i.e. symptoms suggestive of STI or vulvo-vaginitis): - Dysuria - Urgency (including nocturia) - Frequency - Suprapubic tenderness - Urine dipstick test positive for either nitrites or leukocyte esterase - Patient is at increased risk for resistant pathogens, e.g., FQ-resistant or ESBL-producing Enterobacteriacae Exclusion Criteria: - Male sex - Pregnancy or planned pregnancy - Known carriage of nitrofurantoin- or fosfomycin-resistant uropathogens(s) - Concomitant antimicrobial therapy - Use of any antibiotics in the past 7 days - Known or suspected hypersensitivity or allergy to fosfomycin or nitrofurantoin - History of lung or liver reaction or peripheral neuropathy after use of nitrofurantoin or other nitrofurans in the past - Pre-existing polyneuropathy - G6PD deficiency - Symptoms consistent with UTI in the preceding 4 weeks - Active upper UTI (e.g. pyelonephritis, urosepsis: fever > 38.0, flank pain, chills) - Symptoms/signs suggestive of vaginitis or sexually transmitted infection - Indwelling catheter, nephrostomy, ureter stent or other foreign material - Otherwise complicated UTI: - A history of anatomical or functional abnormalities of the urogenital tract: - Congenital abnormalities - Polycystic kidney disease - Obstruction or stricture of renal pelvis, ureter or urethra - Kidney stones - Cystocele - Cystic diverticulae - Change of anatomical proportions (e.g. after ureter implantation) - Chronic vesico-urethral reflux - Neurogenic bladder - Severe chronic renal (creatinine clearance < 30 ml/min) or hepatic dysfunction - Porphyria - Immunosuppression: - Untreated infection with the human immunodeficiency virus (HIV) - Use of high-dose systemic corticosteroids or other immunosuppressive medication - Chemotherapy - Treatment with radiation - Critical illness requiring intensive care - Planned surgery within the next 6 weeks - Inability to take oral drugs - Participation in another prospective clinical trial - Previous enrolment in the proposed study - Inability to understand or to follow the study protocol |
Country | Name | City | State |
---|---|---|---|
Israel | Tel Aviv University | Tel Aviv | |
Poland | Lodz University Hospital | Lodz | |
Switzerland | University Hospitals of Geneva | Geneva |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Geneva | European Commission |
Israel, Poland, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of Participants with Adverse Events as a Measure of Safety and Tolerability | within 28 days post therapy completion | ||
Primary | Number of participants with clinical cure, clinical failure, or indeterminate clinical response (see description below) | Clinical response is defined as either (1) clinical cure, which in turn is defined as complete resolution of symptoms with no recurrence of symptoms or signs of urinary tract infection; (2) clinical failure, defined as the need for additional, or change in, antibiotic treatment due to a urinary tract infection, OR discontinuation due to lack of efficacy; or (3) indeterminate response, defined as either persistence of symptoms without objective evidence of infection (absence of bacteriuria or pyuria) OR any extenuating circumstances precluding a classification or clinical cure/failure. | at 28 days post therapy completion | |
Secondary | Number of participants with bacteriologic cure and with bacteriologic recurrence | Bacteriologic response is defined as either (1) bacteriologic cure, that is, eradication of the infecting strain with no recurrence of bacteriuria (<10x3 cfu/mL) during follow-up; or (2) bacteriologic recurrence, defined as bacteriuria >10x3 cfu/mL. However, bacteriologic recurrence without urinary tract symptoms will be designated asymptomatic bacteriuria and left untreated. | at 28 days post therapy completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04495699 -
Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
|
||
Terminated |
NCT05254808 -
EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
|
Phase 3 | |
Completed |
NCT03680612 -
Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI
|
Phase 2 | |
Completed |
NCT03282006 -
Treating Pyelonephritis an Urosepsis With Pivmecillinam
|
Phase 4 | |
Completed |
NCT03526484 -
The Utility of Urinalysis Prior to In-Office Procedures
|
N/A | |
Completed |
NCT05397782 -
Effects of Flourish on Recurrent Urinary Tract Infection
|
N/A | |
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03687255 -
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
|
Phase 3 | |
Recruiting |
NCT05227937 -
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
|
||
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Completed |
NCT03131609 -
Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
|
||
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Completed |
NCT01333254 -
A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients
|
N/A | |
Terminated |
NCT00594594 -
Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury
|
Phase 1 | |
Completed |
NCT00216853 -
A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection
|
N/A | |
Completed |
NCT00787085 -
The Significance of Funguria in Hospitalized Patients
|
N/A | |
Completed |
NCT05719753 -
The Effectiveness of a Bacteriophobic Coating on Urinary Catheters
|
N/A | |
Recruiting |
NCT05415865 -
The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder
|
Phase 3 | |
Not yet recruiting |
NCT05880329 -
DIagnoSing Care hOme UTI Study
|
||
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|